Investor Relations

Business Overview

Clinical Pipelines

Product Indication Region for
clinical studies
Stage
NC-6004
Cisplatin micelle
Pancreatic cancer Japan/Asia Phase III
clinical study
NSCL,
Bladder,
Biliary tract cancer
USA/EU Phase II
clinical study
Head and Neck cancer USA/EU/Taiwan Phase II
clinical study
VB-111
(In-Licensed from VBL)
Non-replicating Adeno 5 vectors
Planning domestic development Japan
rGBM/Ovarian cancer etc. USA etc. Phase III
clinical study
(Operation by VBL)
ENT product ENT Japan Phase III
clinical study
NC-6300
Epirubicin micelle
Soft tissue sarcoma USA Phase I/II
clinical study
NC-4016
Dach-platinum micelle
Solid cancer USA Phase I
clinical study
NK105
(Out-Licensed to Nippon Kayaku)
Paclitaxel micelle
Breast cancer Japan/Asia Phase II
clinical study
(Operation by Nippon Kayaku)
Gastric cancer Japan Phase II
clinical study
completed
(Operation by Nippon Kayaku)

New pipelines

Next-Generation platform technology
(Active Targeting)
Development phase
Antibody / Drug Conjugated Micelle
(ADCM)
In house development
ADCM-E7974
(In-Licensed from Eisai)
Feasibility Study, etc.
Active - NanoFectTM
Joint Research
siRNA
Feasibility Study, etc.

Pagetop